Compare HP Inc (HPQ) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HP Inc vs Merck & Co., Inc. — how do they compare? HP Inc trades at $30.4 (market cap $29.25B), while Merck & Co., Inc. trades at $145.34 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 12× HP Inc's market cap, and HP Inc pays the higher dividend (3.7%). Which is the better fit depends on your goals — on Pluang, investors hold HP Inc for 70 Days and Merck & Co., Inc. for 98 Days on average.
| HPQ | MRK | |
|---|---|---|
Market Cap | $29.25B | $351.28B |
Volume | 10,025,806 | 7,969,665 |
Sector | Technology | Health |
52-Week High | $35.48 | $156.43 |
52-Week Low | $18.20 | $82.49 |
Typical Hold Time | 70 Days | 98 Days |
Enterprise Value | $35.42B | $398.04B |
Dividend Yield | 3.7% | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HPQ is trading at $30.37, down 5.8% over the past 24 hours, with a bullish technical signal from moving averages but neutral oscillators. The company reported revenue of $55.30 billion in 2025 and has beaten earnings estimates for the last three quarters. Recent news highlights HP's new product launches and a dividend payment scheduled for October 2026, though the stock faces pressure from a forecasted decline in PC sales for 2027.
The outlook for HPQ is mixed, with strong cash flow and consistent earnings beats providing support, but risks from a weakening PC market and high liabilities tempering upside. Analyst consensus is a hold with a price target of $25.75, suggesting cautious optimism amid industry headwinds. Investment opportunity lies in valuation metrics like a low P/E of 12.38, but execution risks remain key.
Merck (MRK) trades at $144.96, up 1.52% today, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with a 72.97% gross margin and 28.07% net income margin for 2025, though its P/E ratio of 113.9 indicates high valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid competitive pressures.
The outlook is mixed: analyst consensus is bullish with a $158.78 price target, but technical indicators and a high P/E suggest near-term caution. Key risks include integration challenges from acquisitions and macroeconomic headwinds affecting pharmaceutical R&D investment. Revenue growth and pipeline execution remain critical for sustained upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About HP Inc
HP Incorporated is a leading provider of computers, printers, and printer supplies. The company's mains segments are personal systems and printing. Its personal systems segment contains notebooks, desktops, and workstations. Its printing segment contains supplies, consumer hardware, and commercial hardware. In 2015, Hewlett-Packard was separated into HP Incorporated and Hewlett Packard Enterprise and the Palo Alto, California-based HP Incorporated sells on a global scale.
Read more on HPQ →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
